The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice
MetadataShow full item record
Background: Thyroid hormones (TH) regulate cholesterol metabolism but their use as lipid-lowering drugs is restricted due to negative cardiac effects. TH mimetic compounds modulating TH receptor ß (THRß) have been designed as potential drugs, reducing serum cholesterol levels while avoiding apparent deleterious cardiac effects. Objective: Using ApoE deficient mice, we examined whether KB3495, a TH mimetic compound, reduces atherosclerosis and if there is a synergistic effect with atorvastatin. The effect of KB3495 was investigated after 10 and 25 weeks. Results: KB3495 treatment reduced atherosclerotic plaque formation in aorta and decreased the cholesteryl ester (CE) content by 57%. Treatment with KB3495 was also associated with a reduction of macrophage content in the atherosclerotic plaques and reduced serum levels of IL-1ß, TNFalpha, IL-6, Interferon ?, MCP-1 and M-CSF. Serum lipoprotein analysis showed no change in total cholesterol levels in ApoB-containing lipoproteins. KB3495 alone increased fecal BA excretion by 90%. The excretion of neutral sterols increased in all groups, with the largest increase in the combination group (350%). After 25 weeks, the animals treated with KB3495 showed 50% lower CE levels in the skin and even further reductions were observed in the combination group where the CE levels were reduced by almost 95% as compared to controls. Conclusion: KB3495 treatment reduced atherosclerosis independently of total cholesterol levels in ApoB-containing lipoproteins likely by stimulation of sterol excretion from the body and by inhibition of the inflammatory response. © 2013 Mörk et al.
Showing items related by title, author, creator and subject.
Pirillo, A.; Catapano, A.; Norata, Giuseppe (2016)© 2016 Bentham Science Publishers. Circulating levels of cholesterol are derived from either endogenous production or intestinal absorption of dietary and biliary cholesterol. Niemann-Pick C1-Like 1 (NPC1L1) is a transmembrane ...
Zhu, Y.; Hayward, P.; Hare, D.; Reid, Christopher; Stewart, A.; Buxton, B. (2013)OBJECTIVES: We evaluated the influence of lipid exposure upon conduit patency in long-term follow-up after primary CABG. METHODS: From a prospectively compiled database, we identified 1207 grafts (436 SV and 771 mixed ...
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline CharacteristicsLonn, E.; Bosch, J.; Pogue, J.; Avezum, A.; Chazova, I.; Dans, A.; Diaz, R.; Fodor, G.; Held, C.; Jansky, P.; Keltai, M.; Keltai, K.; Kunti, K.; Kim, J.; Leiter, L.; Lewis, B.; Liu, L.; Lopez-Jaramillo, P.; Pais, P.; Parkhomenko, A.; Peters, R.; Piegas, L.; Reid, Christopher; Sliwa, K.; Toff, W.; Varigos, J.; Xavier, D.; Yusoff, K.; Zhu, J.; Dagenais, G.; Yusuf, S.; HOPE-3 Investigators (2015)BACKGROUND: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. ...